Pancreatic cancer risk predicted from disease trajectories using deep learning
Davide PlacidoiD, Bo YuaniD, Jessica Xin HjalteliniD, Chunlei ZhengiD, Amalie Dahl HaueiD, Piotr Jaroslaw ChmuraiD, Chen YuaniD, Jihye KimiD, Renato UmetoniD, Gregory C. Antell, Alexander Chowdhury, Alexandra Franz, Lauren K. BraisiD, Elizabeth AndrewsiD, Debora S. MarksiD, Aviv RegeviD, Siamack AyandehiD, Mary T. BrophyiD, Nhan DoiD, Peter KraftiD, Brian Matthew WolpiniD, Nathanael R. FillmoreiD, Michael Hayden RosenthaliD, Søren BrunakiD, Chris SanderiD
Abstract
Pancreatic cancer is an aggressive disease that typically presents late with poor patient outcomes. There is a pronounced medical need for early detection of pancreatic cancer, which can be addressed by identifying high-risk populations. Here we apply artificial intelligence (AI) methods to a dataset of 6 million patient records with 24,000 pancreatic cancer cases in the Danish National Patient Registry (DNPR) and, for comparison, a dataset of three million records with 3,900 pancreatic cancer cases in the United States Department of Veterans Affairs (US-VA) healthcare system. In contrast to existing methods that do not use temporal information, we explicitly train machine learning models on the time sequence of diseases in patient clinical histories and test the ability to predict cancer occurrence in time intervals of 3 to 60 months after risk assessment. For cancer occurrence within 36 months, the performance of the best model (AUROC=0.88, DNPR), trained and tested on disease trajectories, exceeds that of a model without longitudinal information (AUROC=0.85, DNPR). Performance decreases when disease events within a 3 month window before cancer diagnosis are excluded from training (AUROC[3m]=0.83). Independent training and testing on the US-VA dataset reaches comparable performance (AUROC=0.78, AUROC[3m]=0.76). These results raise the state-of-the-art level of performance of cancer risk prediction on real-world data sets and provide support for the design of prediction-surveillance programs based on risk assessment in a large population followed by affordable surveillance of a relatively small number of patients at highest risk. Use of AI on real-world clinical records has the potential to shift focus from treatment of late-stage to early-stage cancer, benefiting patients by improving lifespan and quality of life.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 16
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comprehensive machine-learning survival framework develop a consensus model in large scale multi-center cohorts for pancreatic cancer
Libo Wang, Zaoqu Liu, … Yuling Sun·eLifePeer-reviewed·Oct 17, 2022
- Artificial Intelligence Model: Optimizing Cancer Risk Level Predictions Using Machine learning and deep learning approaches
Areen M. Arabiat, Hamza Abu Owida, … Azlan Bin Abd.Aziz·bioRxiv·Aug 25, 2026
- A machine learning approach to predicting short-term mortality risk in patients starting chemotherapy
Aymen A. Elfiky, Maximilian Julius Pany, … Ziad Obermeyer·bioRxiv·Oct 19, 2017
- Detection of Pancreatic Cancer Using a Methylation-Specific PCR-Based Multi-Cancer Early Detection Test
Hanh T. Pham, Kimberly J. Bussey, … Mark A. Nelson·bioRxiv·May 31, 2026
- Artificial Intelligence Helps to Predict Recurrence and Mortality for Prostate Cancer using Histology Images
O. Eminaga, F. Saad, … S.-R. Leyh-Bannurah·bioRxiv·Jul 27, 2023
- AI-powered Deep Visual Proteomics reveals critical molecular transitions in pancreatic cancer precursors
Jimin Min, Lisa Schweizer, … Anirban Maitra·Cancer DiscoveryPeer-reviewed·Apr 21, 2026